Form 4: Immuneering Director Buys 7,500 Shares

Immuneering Corp. Director Peter Feinberg acquired 7,500 shares of Class A Common Stock at $6.67 per share, increasing his direct beneficial ownership.

Summary

• Peter Feinberg, a Director of Immuneering Corp. (IMRX), purchased 7,500 shares of Class A Common Stock.
• The transaction occurred on October 3, 2025, at a price of $6.67 per share.
• Following this transaction, Peter Feinberg directly beneficially owns 156,766 shares of Class A Common Stock.
• Additionally, he indirectly beneficially owns 392,242 shares as General Partner of PF Associates L.P., 476,615 shares as General Partner of PEF LLC., and 115,441 shares as General Partner of S4K Investments LLC.
• The total beneficial ownership for Peter Feinberg, including direct and indirect holdings, is 1,141,064 shares.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to a director's significant purchase of company stock, indicating strong insider confidence in Immuneering Corp.'s future.

Positives

• A Director's purchase of company stock signals confidence in the company's future prospects and valuation.
• The acquisition of 7,500 shares at $6.67 per share increases the director's direct stake, aligning his interests further with shareholders.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Insider buying, particularly by a director, is often interpreted by the market as a positive signal, suggesting that those closest to the company believe its stock is undervalued or that significant positive developments are anticipated. This action by Immuneering's director could be viewed favorably in the biotechnology or pharmaceutical industry, where confidence in future pipeline success or market positioning is crucial.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive signal, potentially increasing investor confidence and demand for the stock.
• Employees might interpret this as a sign of stability and positive future prospects for the company.

Key Dates

Recommendation

A director's purchase of company stock, especially a substantial amount, is a strong signal of confidence in the company's future prospects and valuation. This insider buying suggests that management believes the stock is currently undervalued or expects significant positive developments, making it a favorable indicator for potential investors.

Keywords

Immuneering, IMRX, Peter Feinberg, Insider Trading, Stock Purchase, Director, Common Stock, SEC Form 4, Rule 10b5-1